Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.660 +0.020 (+0.76%) Streaming Delayed Price Updated: 9:59 AM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 22 23 Next > CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study March 04, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study March 04, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study March 04, 2024 Via ACCESSWIRE Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program January 16, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial March 01, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial March 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial March 01, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering February 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering February 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering February 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering February 20, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D February 20, 2024 Via Investor Brand Network Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 16, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering February 15, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 15, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial February 14, 2024 Via Investor Brand Network Exposures Product Safety TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream February 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter February 12, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap February 01, 2024 Via Investor Brand Network InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial January 30, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria's Submits Investigational New Drug Application January 30, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs January 29, 2024 Via Investor Brand Network TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Shares Company Update in Annual Shareholder Letter January 24, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Releases Annual Letter from the CEO January 24, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study January 17, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study January 17, 2024 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program January 16, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program January 16, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing January 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution January 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 22 23 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.